IL1B and psoriasis: Supplementation with Bifidobacterium infantis in psoriasis patients for 6–8 weeks resulted in reduced pro-inflammatory status by lowering the plasma CRP and LPS-stimulated TNF-α and IL-6 levels; moreover, a multi-strain probiotic also highlighted the improvement in the PASI (Psoriasis Area Severity Index) score and quality of life among psoriasis patients after two months of supplementation, reducing pro-inflammatory cytokines (hs-CRP and IL1-β) and LPS serum levels [167].